REFERRAL GUIDELINE
EARLY DRUG DEVELOPMENT CLINICAL TRIALS

HEAD OF EARLY DRUG DEVELOPMENT: DOCTOR JAYESH DESAI

TARGET AUDIENCE
Early Drug Development (Phase 1) Clinical Trials Unit

PURPOSE
- To assist health professionals with the referral process.
- To ensure all relevant clinical and administrative information accompanies referrals to ensure timely referral processing.

EARLY DRUG DEVELOPMENT CLINICAL TRIALS: REFERRAL REQUIREMENTS

- A completed Peter Mac referral form, addressed to a named clinician – referral form and further information available at www.petermac.org/referrals
- Indicate if the referral is for a specific trial (please name the trial) or for consideration of early phase trial options in general.
- Note we welcome early referrals (patients still receiving final line of standard treatments) to explore treatment options beyond this.
- Results of all relevant investigations, in particular, all current imaging scan reports and recent blood test.
- Anatomical pathology report, including any mutation testing
- Patient’s clinical history, including current performance status and current disease symptoms.
- Information of previous cancer treatment – e.g. Radiotherapy/ Lines of chemotherapy and hospital therapy was received at. Start and stop dates for each line of prior treatment.
- Patient’s current contact details including mobile phone number; where appropriate, please nominate an alternative contact person and their best contact number (e.g. where language is an issue )
- If an interpreter is required nominate the language required.

EARLY DRUG DEVELOPMENT UNIT HAS A DEDICATED MULTIDISCIPLINARY CLINIC AT PARKVILLE EACH MONDAY

- Urgency and clinical review allocation are determined by referral content; all referrals will be triaged within 48 hours by trial medical staff. Lack of information will delay the triaging process.
- We aim for all new referrals to be allocated an appointment within 7 days of receipt of information.
- The referrer will be notified by the medical staff, if the referred patient isn’t considered appropriate for consideration of early phase drug trials by the medical staff.
EARLY DRUG DEVELOPMENT CLINICAL TRIAL ENQUIRIES: CONTACT

For administrative enquires
Please email referral to: patnavEDD@petermac.org

For those patients offered a clinic review an appointment will be made by the administrative team. All administrative enquiries should be directed to: Patient Navigator Early Drug Development: patnavEDD@petermac.org.

For clinical enquiries contact the Clinical Nurse Consultant
Helen Stevens
Clinical Nurse Consultant (Early Drug Development)
Phone: 03 8559 5000 (Switch)
Pager: 1110247

AUTHORISED BY
Doctor Jayesh Desai

AUTHOR/CONTRIBUTORS
Helen Stevens July 2019